Search results for "ciprofloxacin"

showing 10 items of 56 documents

Antibacterial Activity of Propolis Extracts from the Central Region of Romania against Neisseria gonorrhoeae

2021

(1) Background: Sexually transmitted infections (STIs) are among the most common infections worldwide, many of these being caused by Neisseria gonorrhoeae (NG). Increased antimicrobial NG resistance has been reported in recent decades, highlighting the need for new sources of natural compounds with valuable antimicrobial activity. This study aims to determine the effect of propolis extracts on NG strains, including antibiotic-resistant strains. (2) Methods: First void urine samples from presumed positive STI subjects were harvested. DNA was extracted, purified, and amplified via PCR for the simultaneous detection of 6 STIs. The presence of the dcmH, gyrA, and parC genes was checked in the D…

0301 basic medicineMicrobiology (medical)<i>Neisseria gonorrhoeae</i>030106 microbiologyRM1-950Biologymedicine.disease_cause030226 pharmacology & pharmacyBiochemistryMicrobiologyCentral regionArticleMicrobiology03 medical and health sciences0302 clinical medicineantibacterial activitymedicinePharmacology (medical)Statistical analysisciprofloxacin resistanceGeneral Pharmacology Toxicology and PharmaceuticsPropolisAntimicrobialIn vitroNeisseria gonorrhoeaeCiprofloxacinInfectious DiseasesNeisseria gonorrhoeaeTherapeutics. PharmacologyAntibacterial activitypropolis extractsmedicine.drugAntibiotics
researchProduct

Neisseria gonorrhoeae antimicrobial resistance in Spain: a prospective multicentre study.

2021

Abstract Objectives Gonococcal infection is one of the most reported sexually transmitted infections and antimicrobial resistance in Neisseria gonorrhoeae (NG) is challenging for the treatment of this infection. This observational study aimed to describe antimicrobial resistance of NG and epidemiological data from patients with gonococcal infection in eight regions of Spain, for updating the local therapeutic guidelines. Methods MICs of penicillin, cefixime, ceftriaxone, azithromycin, ciprofloxacin, fosfomycin and gentamicin were determined by Etest for all NG isolates recovered from 1 April 2018 to 30 September 2019 from 10 hospitals in Spain. Resistance determinants were identified using …

0301 basic medicineMicrobiology (medical)Malemedicine.medical_specialty030106 microbiologyMicrobial Sensitivity TestsFosfomycinAzithromycinAzithromycinmedicine.disease_cause03 medical and health sciencesGonorrheaSexual and Gender Minorities0302 clinical medicineAntibiotic resistanceCiprofloxacinInternal medicineDrug Resistance BacterialmedicineHumansPharmacology (medical)030212 general & internal medicineProspective StudiesHomosexuality MaleEtestPharmacologybusiness.industryCeftriaxoneNeisseria gonorrhoeaeAnti-Bacterial AgentsPenicillinCiprofloxacinInfectious DiseasesSpainNeisseria gonorrhoeaebusinessCefiximemedicine.drugThe Journal of antimicrobial chemotherapy
researchProduct

Resistance to third-generation cephalosporins in Escherichia coli in the French community: The times they are a-changin'?

2020

Since the early 2000s, Escherichia coli resistance to third-generation cephalosporins (3GCs) has been increasing in all European countries, mainly due to the spread of extended spectrum β-lactamases (ESBLs). Here we present a retrospective study that combines resistance of E. coli to 3GCs and quinolones with data on antibiotic use in the community in a region of Northeastern France.Since 2012, an observational surveillance of antimicrobial resistance and antibiotic use in the community was conducted: data on antimicrobial resistance in E. coli isolates were collected from 11 private laboratories, and consumption data were collected from the three main healthcare insurances.A significant dec…

0301 basic medicineMicrobiology (medical)Veterinary medicinemedicine.drug_classeducationResistance030106 microbiologyCephalosporinAntibioticsContext (language use)Microbial Sensitivity TestsQuinolonesmedicine.disease_causebeta-LactamasesThird generation cephalosporins03 medical and health sciencesNalidixic Acid0302 clinical medicineAntibiotic resistanceCiprofloxacinDrug Resistance BacterialOutpatientsmedicineEscherichia coliPrevalenceHumansPharmacology (medical)030212 general & internal medicineAntibiotic useEscherichia coliComputingMilieux_MISCELLANEOUSEscherichia coli InfectionsRetrospective StudiesResistance (ecology)business.industryThird-generation cephalosporinsGeneral Medicine3. Good healthAnti-Bacterial AgentsCephalosporins[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious Diseases[SDE]Environmental SciencesFrancebusinessInternational journal of antimicrobial agents
researchProduct

Evaluation of a mass spectrometry and Vitek 2 combined protocol for rapid identification and susceptibility testing of Enterobacterales directly from…

2020

Abstract Objective The aim was to evaluate a rapid method which would combine identification and susceptibility testing directly from positive blood cultures for Gram-negative bacilli of the Enterobacterales. Material and methods Gram-negative rods from blood cultures were directly identified by MALDI-TOF. Samples with Enterobacterales were selected for direct antimicrobial susceptibility testing by Vitek 2. The results were compared to those obtained with our laboratory's standard method. Results MALDI-TOF directly from blood cultures identified correctly 83% of the samples. Enterobacterales (n = 68) were identified at gender and species level in 85% of blood cultures with a score >1.7. In…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtySusceptibility testing030106 microbiologyAntimicrobial susceptibilityBacteremiaMicrobial Sensitivity Tests03 medical and health sciences0302 clinical medicineSpecies levelEnterobacteriaceaeInternal medicineEnterobacteralesmedicineHumans030212 general & internal medicineProtocol (science)business.industryAnti-Bacterial AgentsRapid identificationCiprofloxacinAmikacinBlood CultureSpectrometry Mass Matrix-Assisted Laser Desorption-Ionizationbusinessmedicine.drugEnfermedades infecciosas y microbiologia clinica (English ed.)
researchProduct

Evaluation of antimicrobial resistance and virulence of enterococci from equipment surfaces, raw materials and traditional cheeses

2016

Forty enterococci isolated along the production chains of three traditional cheeses (PDO Pecorino Siciliano, PDO Vastedda della Valle del Belìce, and Caciocavallo Palermitano) made in Sicily (southern Italy) were studied for the assessment of their antibiotic resistance and virulence by a combined phenotypic/genotypic approach. A total of 31 Enterococcus displayed resistance to at least one or more of the antimicrobials tested. The strains exhibited high percentages of resistance to erythromycin (52.5%), ciprofloxacin (35.0%), quinupristin–dalfopristin (20.0%), tetracycline (17.5%), and high-level streptomycin (5.0%). The presence of tet(M), cat(pC221), and aadE genes for resistance to tetr…

0301 basic medicineTetracyclineFood HandlingVirulence Factors030106 microbiologyVirulenceMicrobial Sensitivity TestsAntimicrobial resistanceMicrobiologyMicrobiology03 medical and health sciencesAntibiotic resistanceBacterial ProteinsCheeseDrug Resistance BacterialmedicineAnimal rennetAnimal rennet Antimicrobial resistance Enterococcus Raw milk Traditional cheese Virulence Wooden vatAnimalsHumansGram-Positive Bacterial InfectionsbiologyVirulenceRaw milkTraditional cheeseAnimal rennet Antimicrobial resistance Enterococcus Raw milk Traditional cheese Virulence Wooden vatGeneral MedicineRaw milkbiochemical phenomena metabolism and nutritionbiology.organism_classificationAntimicrobialWooden vatAnti-Bacterial AgentsErythromycinCiprofloxacin030104 developmental biologyMilkEnterococcusEquipment and SuppliesItalyStreptomycinEquipment ContaminationCattleEnterococcusFood Sciencemedicine.drugSettore AGR/16 - Microbiologia Agraria
researchProduct

Bayesian approach to urinary ESBL-producing Escherichia coli

2014

This is a retrospective study about the prevalence of ESBL-producing Escherichia coli (EEC) in urinary specimens from patients from the Comunitat Valenciana from January 2007 to December 2008. Data were retrieved from RedMIVA, and Bayesian generalized linear mixed models were considered to study the prevalence of EEC with regard to demographical and microbiological factors. The total number of infections considered was 164,502, the amount of urinary isolates was 70,827 belonging to 49,304 different patients, and 5,161 (7.3%) of the urinary isolates were EEC. Three out of four E. coli were isolated in women (76.8%), men showed higher rates of EEC (9.7% in men vs. 6.5% in women). EEC patients…

0301 basic medicinemedicine.medical_specialtyUrinary system030106 microbiologyPharmacologymedicine.disease_causePharmacovigilance03 medical and health sciencesAntibiotic resistanceInternal medicineControlMedicineRisk factorEscherichia colibusiness.industryMicrobiologia mèdicaRetrospective cohort studyAntimicrobialOmicsCiprofloxacinstomatognathic diseasesEstadística bayesianaBacteris patògensAntimicrobialbusinessmedicine.drug
researchProduct

High susceptibility of MDR and XDR Gram-negative pathogens to biphenyl-diacetylene-based difluoromethyl-allo-threonyl-hydroxamate LpxC inhibitors

2016

International audience; Inhibitors of uridine diphosphate-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC, which catalyses the first, irreversible step in lipid A biosynthesis) are a promising new class of antibiotics against Gram-negative bacteria. The objectives of the present study were to: (i) compare the antibiotic activities of three LpxC inhibitors (LPC-058, LPC-011 and LPC-087) and the reference inhibitor CHIR-090 against Gram-negative bacilli (including MDR and XDR isolates); and (ii) investigate the effect of combining these inhibitors with conventional antibiotics.MethodsMICs were determined for 369 clinical isolates (234 Enterobacteriaceae and 135 non-fermentati…

Acinetobacter baumanniiThreonine0301 basic medicineMicrobiology (medical)Klebsiella pneumoniaemedicine.drug_class030106 microbiologyAntibioticsMicrobial Sensitivity TestsHydroxamic Acidsmedicine.disease_causebeta-LactamasesAmidohydrolasesMicrobiology03 medical and health sciencesBacterial ProteinsEnterobacteriaceae[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyDrug Resistance Multiple BacterialGram-Negative BacteriaEscherichia colipolycyclic compoundsmedicineHumansPharmacology (medical)Enzyme InhibitorsOriginal ResearchPharmacologybiologyPseudomonas aeruginosaEnterobacteriaceae Infectionsbiochemical phenomena metabolism and nutritionbacterial infections and mycosesAntimicrobialbiology.organism_classificationEnterobacteriaceaeAnti-Bacterial Agents3. Good healthAcinetobacter baumanniiCiprofloxacinKlebsiella pneumoniae[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyInfectious DiseasesAmikacinPseudomonas aeruginosalipids (amino acids peptides and proteins)medicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Re: Antimicrobial Resistance in More Than 100,000 Escherichia coli Isolates According to Culture Site and Patient Age, Gender, and Location

2011

ABSTRACT Escherichia coli and the antimicrobial pressure exerted on this microorganism can be modulated by factors dependent on the host. In this paper, we describe the distribution of antimicrobial resistance to amikacin, tobramycin, ampicillin, amoxicillin clavulanate, cefuroxime, cefoxitin, cefotaxime, imipenem, ciprofloxacin, fosfomycin, nitrofurantoin, and trimetoprim-sulfametoxazole in more than 100,000 E. coli isolates according to culture site and patient age, gender, and location. Bayesian inference was planned in all statistical analysis, and Markov chain Monte Carlo simulation was employed to estimate the model parameters. Our findings show the existence of a marked difference in…

AdultMaleCefotaximeAdolescentmedicine.drug_classUrologyAntibioticsCefotaximeDrug resistanceFosfomycinBiologymedicine.disease_causeEpidemiology and SurveillanceMicrobiologyYoung AdultAntibiotic resistanceFosfomycinCiprofloxacinPatient ageDrug Resistance Multiple BacterialEscherichia coliHumansMedicinePharmacology (medical)ChildAmikacinEscherichia coliEscherichia coli InfectionsAgedRetrospective StudiesAntibacterial agentAged 80 and overPharmacologybusiness.industryInfantMiddle AgedAntimicrobialAnti-Bacterial AgentsImipenemInfectious DiseasesNitrofurantoinAmikacinChild PreschoolTobramycinAmpicillinFemalebusinessmedicine.drugJournal of Urology
researchProduct

Antibacterial susceptibility patterns of Porphyromonas gingivalis isolated from chronic Periodontitis patients

2010

Objectives: To test the antimicrobial sensitivity of Porphyromonas gingivalis to a panel of eight orally administrable antibiotics in chronic periodontal diseases and to evaluate factors associated with periodontitis in adult patients. Study Design: A total of fifty strains of P. gingivalis were isolated from one hundred and twenty adult patients with chronic perio-dontitis. Identification of bacteria was carried out by anaerobic culture and biochemical tests. Selected colonies of P. gingivalis were used to evaluate the antibacterial activities of penicillin, metronidazole, amoxicillin, amoxicillin/clavulanic acid, clindamycin, doxy-cycline, ciprofloxacin and azithromycin. Results: Most of …

AdultMalemedicine.drug_classAntibioticsAdministration OralMicrobial Sensitivity TestsAzithromycinMicrobiologyClavulanic acidmedicineHumansPeriodontitisGeneral DentistryPorphyromonas gingivalisPeriodontitisbiologybusiness.industryMiddle AgedAmoxicillin:CIENCIAS MÉDICAS [UNESCO]medicine.diseasebiology.organism_classificationChronic periodontitisAnti-Bacterial AgentsCiprofloxacinOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASChronic DiseaseFemaleSurgerybusinessPorphyromonas gingivalismedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

2006

1. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Operative Unit of Gastroenterology, St Camillo-Forlanini Hospital, Rome, Italy. prantera@tin.it BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. AIM: To evaluate the difference in efficacy between once and twice/daily oral administration of rifaximin and placebo in the treatment of active Crohn's …

AdultMalemedicine.medical_specialtyPlacebo-controlled studyCIPROFLOXACINPlaceboGastroenterologyInflammatory bowel diseaseDrug Administration ScheduleRifaximinPlaceboschemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodIntestinal mucosaINFLAMMATORY-BOWEL-DISEASE C-REACTIVE PROTEIN ULCERATIVE-COLITIS METRONIDAZOLE CIPROFLOXACIN MANAGEMENT RECURRENCE DIARRHEA ANTIBODY MODERATEInternal medicinemedicineMANAGEMENTHumansPharmacology (medical)RECURRENCEAntibacterial agentCrohn's diseaseChi-Square DistributionHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.diseaseRifamycinsUlcerative colitisDIARRHEAC-REACTIVE PROTEINAnti-Bacterial AgentsSurgeryRifaximinTreatment OutcomechemistryULCERATIVE-COLITISANTIBODYMETRONIDAZOLEAcute Diseaserifaximin.crohn's diseaseMODERATEFemalebusinessINFLAMMATORY-BOWEL-DISEASE
researchProduct